Metagenomi (MGX) Competitors $1.74 -0.01 (-0.57%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.06 (+3.39%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. YMAB, SLRN, IMMP, PROK, HUMA, ITOS, SLDB, CRVS, CRGX, and CDTXShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Y-mAbs Therapeutics (YMAB), Acelyrin (SLRN), Immutep (IMMP), ProKidney (PROK), Humacyte (HUMA), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Corvus Pharmaceuticals (CRVS), CARGO Therapeutics (CRGX), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Y-mAbs Therapeutics Acelyrin Immutep ProKidney Humacyte iTeos Therapeutics Solid Biosciences Corvus Pharmaceuticals CARGO Therapeutics Cidara Therapeutics Metagenomi (NASDAQ:MGX) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership. Do analysts rate MGX or YMAB? Metagenomi presently has a consensus target price of $13.00, suggesting a potential upside of 647.13%. Y-mAbs Therapeutics has a consensus target price of $17.40, suggesting a potential upside of 324.39%. Given Metagenomi's higher probable upside, equities analysts clearly believe Metagenomi is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Y-mAbs Therapeutics 2 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.82 Which has preferable earnings and valuation, MGX or YMAB? Y-mAbs Therapeutics has higher revenue and earnings than Metagenomi. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.30M1.24-$68.25M-$2.62-0.66Y-mAbs Therapeutics$87.69M2.11-$21.43M-$0.67-6.12 Which has more volatility and risk, MGX or YMAB? Metagenomi has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Does the MarketBeat Community favor MGX or YMAB? Y-mAbs Therapeutics received 117 more outperform votes than Metagenomi when rated by MarketBeat users. However, 95.45% of users gave Metagenomi an outperform vote while only 63.01% of users gave Y-mAbs Therapeutics an outperform vote. CompanyUnderperformOutperformMetagenomiOutperform Votes2195.45% Underperform Votes14.55%Y-mAbs TherapeuticsOutperform Votes13863.01% Underperform Votes8136.99% Do insiders and institutionals hold more shares of MGX or YMAB? 70.8% of Y-mAbs Therapeutics shares are held by institutional investors. 22.5% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is MGX or YMAB more profitable? Y-mAbs Therapeutics has a net margin of -28.22% compared to Metagenomi's net margin of -134.27%. Y-mAbs Therapeutics' return on equity of -24.61% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-134.27% -43.23% -18.86% Y-mAbs Therapeutics -28.22%-24.61%-18.49% Does the media prefer MGX or YMAB? In the previous week, Y-mAbs Therapeutics had 13 more articles in the media than Metagenomi. MarketBeat recorded 14 mentions for Y-mAbs Therapeutics and 1 mentions for Metagenomi. Y-mAbs Therapeutics' average media sentiment score of 0.22 beat Metagenomi's score of 0.00 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Metagenomi Neutral Y-mAbs Therapeutics Neutral SummaryY-mAbs Therapeutics beats Metagenomi on 16 of the 19 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.05M$2.91B$5.44B$7.80BDividend YieldN/A1.91%5.43%4.30%P/E Ratio-0.6629.2222.1418.40Price / Sales1.24481.28389.70101.30Price / CashN/A168.6838.2034.62Price / BookN/A3.036.664.18Net Income-$68.25M-$72.17M$3.21B$247.71M7 Day Performance14.47%9.34%5.83%6.45%1 Month Performance9.43%-6.30%-4.32%-3.14%1 Year Performance-74.18%-19.67%17.83%5.40% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi1.2734 of 5 stars$1.74-0.6%$13.00+647.1%-74.1%$65.05M$52.30M-0.66236Positive NewsGap UpYMABY-mAbs Therapeutics3.6135 of 5 stars$4.93+2.1%$18.30+271.2%-73.0%$222.93M$87.69M-9.13150Analyst DowngradeAnalyst RevisionNews CoveragePositive NewsSLRNAcelyrin3.4184 of 5 stars$2.18-2.2%$9.60+340.4%-52.5%$219.98MN/A-0.89135Positive NewsIMMPImmutep1.0903 of 5 stars$1.49+2.1%$8.50+470.5%-35.1%$216.88M$5.14M0.002,021News CoveragePositive NewsPROKProKidney2.3937 of 5 stars$0.74+1.2%$5.00+575.7%-63.5%$216.60M$76,000.00-1.353Insider TradePositive NewsHUMAHumacyte2.2946 of 5 stars$1.49-2.6%$13.71+820.4%-61.3%$215.82M$1.57M-1.11150Analyst RevisionITOSiTeos Therapeutics2.2765 of 5 stars$5.53-2.1%$25.75+365.6%-29.4%$211.21M$35M-1.7690SLDBSolid Biosciences3.555 of 5 stars$2.71+0.4%$15.67+478.1%-58.2%$210.01M$8.09M-0.89100Analyst RevisionNews CoveragePositive NewsGap UpCRVSCorvus Pharmaceuticals2.8474 of 5 stars$3.03+1.7%$15.67+417.1%+142.4%$206.45MN/A-3.2630Positive NewsGap UpCRGXCARGO Therapeutics2.9867 of 5 stars$4.46+4.7%$15.00+236.3%-75.8%$205.39MN/A-1.05116Positive NewsCDTXCidara Therapeutics4.1465 of 5 stars$18.74+2.9%$39.14+108.9%+74.8%$205.26M$1.28M-0.7390Upcoming Earnings Related Companies and Tools Related Companies Y-mAbs Therapeutics Competitors Acelyrin Competitors Immutep Competitors ProKidney Competitors Humacyte Competitors iTeos Therapeutics Competitors Solid Biosciences Competitors Corvus Pharmaceuticals Competitors CARGO Therapeutics Competitors Cidara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
